| [1] |
Rasouly HM, Groopman EE, Heyman-Kantor R, et al. The burden of candidate pathogenic variants for kidney and genitourinary disorders emerging from exome sequencing [J]. Ann Intern Med, 2019, 170(1): 11-21.
|
| [2] |
Groopman EE, Marasa M, Cameron-Christie S, et al. Diagnostic utility of exome sequencing for kidney disease [J]. N Engl J Med, 2019, 380(2): 142-151.
|
| [3] |
Dahl NK, Bloom MS, Chebib FT, et al. The clinical utility of genetic testing in the diagnosis and management of adults with chronic kidney disease [J]. J Am Soc Nephrol, 2023, 34(12): 2039-2050.
|
| [4] |
Devuyst O, Knoers NVAM, Remuzzi G, et al. Rare inherited kidney diseases: challenges, opportunities, and perspectives [J]. Lancet, 2014, 383(9931): 1844-1859.
|
| [5] |
Mann N, Braun DA, Amann K, et al. Whole-exome sequencing enables a precision medicine approach for kidney transplant recipients [J]. J Am Soc Nephrol, 2019, 30(2): 201-215.
|
| [6] |
Ben-Moshe Y, Shlomovitz O, Atias-Varon D, et al. Diagnostic utility of exome sequencing among Israeli children with kidney failure [J]. Kidney Int Rep, 2023, 8(10): 2126-2135.
|
| [7] |
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease [J]. Kidney Int, 2024, 105(4S): S117-S314.
|
| [8] |
Vivante A. Genetics of chronic kidney disease [J]. N Engl J Med, 2024, 391(7): 627-639.
|
| [9] |
Li AS, Ingham JF, Lennon R. Genetic disorders of the glomerular filtration barrier [J]. Clin J Am Soc Nephrol, 2020, 15(12): 1818-1828.
|
| [10] |
Pollak MR, Friedman DJ. The genetic architecture of kidney disease [J]. Clin J Am Soc Nephrol, 2020, 15(2): 268-275.
|
| [11] |
Groopman EE, Povysil G, Goldstein DB, et al. Rare genetic causes of complex kidney and urological diseases [J]. Nat Rev Nephrol, 2020, 16(11): 641-656.
|
| [12] |
Sanchez-Rodriguez E, Southard CT, Kiryluk K. GWAS-based discoveries in IgA nephropathy, membranous nephropathy, and steroid-sensitive nephrotic syndrome [J]. Clin J Am Soc Nephrol, 2021, 16(3): 458-466.
|
| [13] |
Friedman DJ, Pollak MR. Apolipoprotein L1 and kidney disease in African Americans [J]. Trends Endocrinol Metab, 2016, 27(4): 204-215.
|
| [14] |
Xie J, Liu L, Mladkova N, et al. The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis [J]. Nat Commun, 2020, 11(1): 1600.
|
| [15] |
丁西满，王世然. 遗传性肾脏病的分类和临床研究近况[J]. 国外医学遗传学分册，1986, (3): 123-126.
|
| [16] |
Drovandi S, Lipska-Ziętkiewicz BS, Ozaltin F, et al. Oral coenzyme Q10 supplementation leads to better preservation of kidney function in steroid-resistant nephrotic syndrome due to primary coenzyme Q10 deficiency [J]. Kidney Int, 2022, 102(3): 604-612.
|
| [17] |
戴阳丽，罗小平，巩纯秀，等. 中国儿童Bardet-Biedl综合征诊治专家共识[J]. 中国实用儿科杂志，2022, 37(4): 241-247.
|
| [18] |
Muntean C, Chirtes C, Baczoni B, et al. PAX2 gene mutation in pediatric renal disorders-a narrative review [J]. Int J Mol Sci, 2023, 24(16): 12737.
|
| [19] |
Adam J, Browning AC, Vaideanu D, et al. A wide spectrum of phenotypes in a family with renal coloboma syndrome caused by a PAX2 mutation [J]. Clin Kidney J, 2013, 6(4): 410-413.
|
| [20] |
Ozaltin F, Li B, Rauhauser A, et al. DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN [J]. J Am Soc Nephrol, 2013, 24(3): 377-384.
|
| [21] |
Lemaire M, Frémeaux-Bacchi V, Schaefer F, et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome [J]. Nat Genet, 2013, 45(5): 531-536.
|
| [22] |
Kashtan CE. Alport syndrome: achieving early diagnosis and treatment [J]. Am J Kidney Dis, 2021, 77(2): 272-279.
|
| [23] |
Deltas C, Pierides A. COL4A3/COL4A4 heterozygous mutations with TBMN presenting as focal segmental glomerulosclerosis [J]. Kidney Int, 2015, 87(4): 859.
|
| [24] |
Malone AF, Phelan PJ, Hall G, et al. Rare hereditary COL4A3/COL4A4 variants may be mistaken for familial focal segmental glomerulosclerosis [J]. Kidney Int, 2014, 86(6): 1253-1259.
|
| [25] |
Funk SD, Lin MH, Miner JH. Alport syndrome and pierson syndrome: diseases of the glomerular basement membrane [J]. Matrix Biol, 2018, 71-72: 250-261.
|
| [26] |
Savige J, Harraka P. Pathogenic LAMA5 variants and kidney disease [J]. Kidney360, 2021, 2(12): 1876-1879.
|
| [27] |
Goldberg S, Adair-Kirk TL, Senior RM, et al. Maintenance of glomerular filtration barrier integrity requires laminin alpha5 [J]. J Am Soc Nephrol, 2010, 21(4): 579-586.
|
| [28] |
Kaimori JY, Kikkawa Y, Motooka D, et al. A heterozygous LAMA5 variant may contribute to slowly progressive, vinculin-enhanced familial FSGS and pulmonary defects [J]. JCI Insight, 2022, 7(23): e158378.
|
| [29] |
Deepthi B, Sivakumar RR, Krishnasamy S, et al. Congenital nephrotic syndrome with diffuse mesangial sclerosis caused by compound heterozygous mutation in LAMA5 gene [J]. Pediatr Nephrol, 2024, 39(5): 1421-1425.
|
| [30] |
Sunwoo Y, Choi N, Min J, et al. Case report: genetic defects in laminin α5 cause infantile steroid-resistant nephrotic syndrome [J]. Front Pediatr, 2022, 10: 1054082.
|
| [31] |
Voskarides K, Papagregoriou G, Hadjipanagi D, et al. COL4A5 and LAMA5 variants co-inherited in familial hematuria: digenic inheritance or genetic modifier effect? [J]. BMC Nephrol, 2018, 19(1): 114.
|
| [32] |
Daga S, Fallerini C, Furini S, et al. Non-collagen genes role in digenic Alport syndrome [J]. BMC Nephrol, 2019, 20(1): 70.
|
| [33] |
Trautmann A, Bodria M, Ozaltin F, et al. Spectrum of steroid-resistant and congenital nephrotic syndrome in children: the PodoNet registry cohort [J]. Clin J Am Soc Nephrol, 2015, 10(4): 592-600.
|
| [34] |
Bierzynska A, McCarthy HJ, Soderquest K, et al. Genomic and clinical profiling of a national nephrotic syndrome cohort advocates a precision medicine approach to disease management [J]. Kidney Int, 2017, 91(4): 937-947.
|
| [35] |
Meliambro K, He JC, Campbell KN. Podocyte-targeted therapies- progress and future directions [J]. Nat Rev Nephrol, 2024, 20(10): 643-658.
|
| [36] |
Jungraithmayr TC, Hofer K, Cochat P, et al. Screening for NPHS2 mutations may help predict FSGS recurrence after transplantation [J]. J Am Soc Nephrol, 2011, 22(3): 579-585.
|
| [37] |
Falcone MP, Pritchard-Jones K, Brok J, et al. Long-term kidney function in children with Wilms tumour and constitutional WT1 pathogenic variant [J]. Pediatr Nephrol, 2022, 37(4): 821-832.
|
| [38] |
McConnachie DJ, Stow JL, Mallett AJ. Ciliopathies and the kidney: a review [J]. Am J Kidney Dis, 2021, 77(3): 410-419.
|
| [39] |
Anvarian Z, Mykytyn K, Mukhopadhyay S, et al. Cellular signalling by primary cilia in development, organ function and disease [J]. Nat Rev Nephrol, 2019, 15(4): 199-219.
|
| [40] |
Hildebrandt F, Benzing T, Katsanis N. Ciliopathies [J]. N Engl J Med, 2011, 364(16): 1533-1543.
|
| [41] |
Tory K, Lacoste T, Burglen L, et al. High NPHP1 and NPHP6 mutation rate in patients with Joubert syndrome and nephronophthisis: potential epistatic effect of NPHP6 and AHI1 mutations in patients with NPHP1 mutations [J]. J Am Soc Nephrol, 2007, 18(5): 1566-1575.
|
| [42] |
Reiter JF, Leroux MR. Genes and molecular pathways underpinning ciliopathies [J]. Nat Rev Mol Cell Biol, 2017, 18(9): 533-547.
|
| [43] |
孙咏琪，王辉. HNF1B肾病及其肾脏囊性表型发生机制研究进展[J]. 中华儿科杂志，2025, 63(11): 1270-1274.
|
| [44] |
Faguer S, Decramer S, Chassaing N, et al. Diagnosis, management, and prognosis of HNF1B nephropathy in adulthood [J]. Kidney Int, 2011, 80(7): 768-776.
|
| [45] |
Goknar N, Ekici Avci M, Uckardes D, et al. Hepatocyte nuclear factor 1 beta mutation-associated newborn onset of glomerulocystic kidney disease: a case presentation [J]. Medeni Med J, 2021, 36(4): 352-355.
|
| [46] |
Groopman EE, Rasouly HM, Gharavi AG. Genomic medicine for kidney disease [J]. Nat Rev Nephrol, 2018, 14(2): 83-104.
|
| [47] |
KDIGO Conference Participants. Genetics in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference [J]. Kidney Int, 2022, 101(6): 1126-1141.
|
| [48] |
Franceschini N, Feldman DL, Berg JS, et al. Advancing genetic testing in kidney diseases: report from a National Kidney Foundation Working Group [J]. Am J Kidney Dis, 2024, 84(6): 751-766.
|
| [49] |
Savige J, Lipska-Zietkiewicz BS, Watson E, et al. Guidelines for genetic testing and management of Alport syndrome [J]. Clin J Am Soc Nephrol, 2022, 17(1): 143-154.
|